Home >> Tag Archives: Beckman Coulter Diagnostics

Tag Archives: Beckman Coulter Diagnostics

Beckman Coulter adds 6-AM and BUP assays, 4/18

April 2018—Beckman Coulter Diagnostics announced the addition of 6-acetylmorphine and buprenorphine assays to its menu of drugs-of-abuse tests for use on its AU chemistry analyzers (AU480, AU680, AU5800). The Syva Emit II Plus 6-AM assay provides a convenient and quick way to selectively screen for heroin use, in place of methods such as gas chromatography and mass spectrometry.

Read More »

Beckman introduces Access Sensitive Estradiol

April 11, 2018—Beckman Coulter Diagnostics announced the launch of its Access Sensitive Estradiol assay in the U.S. and in a majority of markets worldwide. The test is commonly ordered for detecting estradiol levels in women, children, and men. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions. It has a broad ...

Read More »

FDA-cleared Access AMH immunoassay, 3/18

March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman’s ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.

Read More »

Thyroid stimulating hormone assay, 3/16

March 2016—Beckman Coulter Diagnostics obtained a CE mark for and released its new Access TSH (3rd IS) assay for use with the company’s Access family of immunoassay systems. This assay is the next generation of the Access Hypersensitive hTSH and Access Fast hTSH assays for the quantitative determination of human thyroid stimulating hormone (TSH, thyrotropin) levels in human serum and plasma.

Read More »
CAP TODAY
X